At its Q3 2026 results briefing, Botuo Biotech said it will retain POCT rapid diagnostics as its core business, expand its product matrix, accelerate domestic and overseas registrations/certifications, and advance a microfluidic fluorescent detection platform and high-end microfluidic chip reagent development to strengthen POCT competitiveness. The company said it is also deploying an industrial investment platform—via equity stakes, M&A and participation in industry funds—to explore frontier me

2026-11-11

At its Q3 2026 results briefing, Botuo Biotech said it will retain POCT rapid diagnostics as its core business, expand its product matrix, accelerate domestic and overseas registrations/certifications, and advance a microfluidic fluorescent detection platform and high-end microfluidic chip reagent development to strengthen POCT competitiveness. The company said it is also deploying an industrial investment platform—via equity stakes, M&A and participation in industry funds—to explore frontier medical areas including brain–computer interfaces (BCI) and AI-driven healthcare, aiming to open long-term potential growth avenues.